際際滷

際際滷Share a Scribd company logo

Straumann_ITI-WS-EN

A
ams-m

Straumann and botiss have entered into an agreement to combine their strengths in providing complete oral tissue regeneration solutions worldwide. Straumann will have exclusive rights to distribute botiss regenerative products in most Western/Central European countries and Americas, while botiss will distribute Straumann's Emdogain in Germany, Eastern Europe, and the Middle East. The companies plan to begin cross-distribution in initial countries in October 2014. At the ITI World Symposium, Straumann will present research on their Roxolid minimally invasive implants and PURE ceramic implant, and introduce new prosthetic components and CADCAM enhancements.

1 of 3
Download to read offline
Page 1/3 Media Release Straumann and botiss team up to provide complete dental regeneration solutions worldwide Bilateral distribution agreement to be announced at ITI World Symposium New products and solutions rolled out Research and clinical experience presented on reduced invasiveness with Roxolid速 small implants and on the new Straumann速 PURE ceramic implant Geneva, 23 April 2014 At the ITI World Symposium, which opens tomorrow in Geneva, Straumann and botiss are announcing their intention to combine their strengths to provide complete oral tissue regeneration solutions to dental professionals worldwide. According to an agreement between the two companies, Straumann will have exclusive rights to distribute botiss regenerative system products initially in most Western and Central European countries and the Americas, with co-distribution in Germany. At the same time, botiss will receive rights to distribute Straumanns unique regenerative product Emdogain速 in Germany as well as in parts of Eastern Europe and the Middle East. In addition, Straumann has been granted a call option to acquire botiss shares which, if exercised, could lead to a stake in the German company of up to 30% in 2017. Based in Berlin, botiss biomaterials is Europes second largest supplier of oral tissue regeneration products. Its full range of clinically proven, high quality solutions includes membranes for guided tissue and bone regeneration, a full range of bovine, allogenica and synthetic bone graft materials, as well as soft-tissue-graft products. botiss is a fast-growing entrepreneurial company, whose products are used in leading clinics across Europe and are backed by many years of clinical experience. The company prides itself in innovations, such as its maxgraft速 bonering for simultaneous implant placement and bone augmentation, as well as the maxgraft速 bonebuilder, a bone block customized for individual patients. Straumanns CEO, Marco Gadola commented: botiss will enable us to offer an unparalleled range of regenerative solutions to support implant and periodontal procedures. Their quality, effectiveness, handling characteristics and clinical track record will have great appeal to our customers as will the possibility to obtain every component for a complete solution from one company. botiss specializes in biomaterials for dental bone and tissue regeneration. Having gained a leading position in Europe, the company is looking to establish itself in other regions. botiss is privately owned and was founded by its two managing partners, Oliver Bielenstein and Dr Dra転en Tadi, in 2008. Dr Tadi noted: Our products, fields of interest and geographical footprints complement each other perfectly. Straumanns leadership in implant dentistry, its global strength and sales channels will help drive our geographic expansion. The possibilities of brand leverage and of distributing Emdogain are highly attractive and will benefit our partners in Eastern Europe and the Middle East. The two companies plan to begin distributing the respective products in initial countries in October 2014 and will work together to expedite regulatory clearances in American and Asian markets.
Page 2/3 ITI World Symposium provides excellent platform for new research and products With more than 4000 participants, the ITI World Symposium is the leading academic event in oral implantology. Straumann is benefitting from this years event in Geneva to announce the roll-out of several innovative products and solutions, in addition to promoting its products through research updates. Roxolid速 minimally invasive implants1 now available throughout Europe Following initial introductions in selected markets, Straumanns full range of Roxolid implants is now available throughout Europe. This includes the small-diameter and 4mm short implant versions, which reduce invasiveness by avoiding bone augmentation procedures. Presentations in Geneva will refer to two and five year data for the 4mm implant2,3 and three- year clinical data on reduced-diameter implants4 , showing high survival rates and minimal marginal bone loss. Clinicians observations that short implants can lead to fewer complications, less morbidity, lower costs and more predictable outcomes5 will also be discussed. These and other factors make short implants an attractive option, often providing a completely different strategy for implant placement. Straumann速 PURE Ceramic Implant officially launched Straumanns innovative ceramic implant, which was presented at the EAO last October, has completed its controlled market release. Based on the positive feedback and clinical results (97.6% success and survival rates6 ), which will be presented in Geneva, the implant is now generally available to customers in Europe under the brand name Straumann速 PURE. The implant has exceptional esthetic properties with a translucent ivory color like natural tooth roots. It has a specially-developed ZLA速 surface to enhance and shorten the healing process and to provide highly predictable osseointegration. Its manufacture involves several innovations including a test procedureto assure the stability of every implant. New prosthetic components for fixed full-arch restorations To address the challenging needs of edentulous patients who want reliable, esthetic, full-arch dentures that are fixed, rather than removable, Straumann is introducing a new range of screw-retained implant abutments that offer increased flexibility. In addition to having low profiles, the new abutments are available with 17属 and 30属 angulations for challenging situations where the posterior implant has to be tilted. Straumann is also preparing the launch of new custom-milled framework components for final fixed prostheses. Broader CADCAM options with efficiency and productivity gains The Group is also announcing further enhancements to its CADCAM system. The latest software release, CARES速 Visual 8.8, offers further streamlined prosthetic solutions and a broader range of product combinations. The CARES X-Stream workflow, which significantly reduces turnaround time and shipping costs, can now be used for Straumanns Variobase abutment. Numerous restorative options are available for the latter, which offers a highly cost-effective, complete prosthetic solution with an original Straumann connection. For customers who want CADCAM custom prosthetics but do not have the requisite scanning capabilities, Straumann offers a Scan&Shape service, which has also been enhanced with additional functionality. 3M ESPE Trusted Connection Straumann and 3M ESPE are jointly announcing a trusted connection for the 3M True Definition Scanner. This enables dentists7 to obtain original CARES prosthetic solutions for implant- or tooth-borne restorations from just a single intra-oral scan and through a seamless workflow. The trusted connection is a further example of how Straumann is teaming up with leading providers to offer more options, simpler solutions, greater precision and higher productivity to dental professionals. Together with 3M ESPE, Dental Wings and Innovation
Page 3/3 MediTech, Straumann offers a completely digital workflow from digital impression to finished CAM prosthetic with an excellent level of choice, flexibility and precision Further details of the aforementioned Straumann solutions are published in the current edition of Starget (www.straumann.com/starget). About Straumann Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners. Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland. Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01 E-mail: corporate.communication@straumann.com / investor.relations@straumann.com Homepage: www.straumann.com Contacts: Corporate Communication: Mark Hill, +41 (0)61 965 13 21 Thomas Konrad, +41 (0)61 965 15 46 Investor Relations: Fabian Hildbrand, +41 (0)61 965 13 27 Disclaimer This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. # # # 1 Less loss of biological tissues because of smaller implant bed and in case of reduced number of soft and hard tissue augmentation. 2 Slotte C, Gr淡nningsaeter A, Halm淡y AM, hrnell LO, Stroh G, Isaksson S, Johansson L, Mordenfeld A, Eklund J, Embring J. Four-millimeter implants supporting fixed partial dental prostheses in the severely resorbed posterior mandible: two-year results. Clin Implant Dent Relat Res. 2012 May;14 Suppl 1:e46-58. Epub 2011 May 20. 3 Slotte C, Gronningsaeter A, Halmoy, AM, Ohrnell LA, Mordenfeld A, Isaksson S, Johansson LA: Four-millimeter-long posterior- mandible implants: 5-year outcomes of a prospective multicenter study. Clin Implant Dent Realt Res. (submitted) 4 Quirynen M, Al-Nawas B, Meijer HJ, Razavi A, Reichert TE, Schimmel M, Storelli S, Romeo E; the Roxolid Study Group. Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double- blind, randomized controlled trial. Clin Oral Implants Res. 2014 Apr 9. [Epub ahead of print] 5 H辰mmerle C: Interview published in Starget 1/2014. Cochran D: Presentation at the Straumann Corporate Forum, EAO Dublin 2013. Al-Nawas B, H辰mmerle C: Presentations at the Straumann Corporate Forum, ITI World Symposium, Geneva 2014. 6 Gahlert M, Kniha H, Weingart D, Schild S, Eicholz P, Nickles K, Borman K-H, Prospective Open Label Single Arm Study to Evaluate the Performance of Straumann Ceramic Implants Monotype CIM (Zirconium dioxide) in single tooth gaps in the maxilla and mandible. EAO 2013, Poster 252, Clin. Oral Impl. Res. 24 (Suppl. s9), 2013, p. 123. 7 Available initially in US, Iberia and Benelux.

More Related Content

Straumann_ITI-WS-EN

  • 1. Page 1/3 Media Release Straumann and botiss team up to provide complete dental regeneration solutions worldwide Bilateral distribution agreement to be announced at ITI World Symposium New products and solutions rolled out Research and clinical experience presented on reduced invasiveness with Roxolid速 small implants and on the new Straumann速 PURE ceramic implant Geneva, 23 April 2014 At the ITI World Symposium, which opens tomorrow in Geneva, Straumann and botiss are announcing their intention to combine their strengths to provide complete oral tissue regeneration solutions to dental professionals worldwide. According to an agreement between the two companies, Straumann will have exclusive rights to distribute botiss regenerative system products initially in most Western and Central European countries and the Americas, with co-distribution in Germany. At the same time, botiss will receive rights to distribute Straumanns unique regenerative product Emdogain速 in Germany as well as in parts of Eastern Europe and the Middle East. In addition, Straumann has been granted a call option to acquire botiss shares which, if exercised, could lead to a stake in the German company of up to 30% in 2017. Based in Berlin, botiss biomaterials is Europes second largest supplier of oral tissue regeneration products. Its full range of clinically proven, high quality solutions includes membranes for guided tissue and bone regeneration, a full range of bovine, allogenica and synthetic bone graft materials, as well as soft-tissue-graft products. botiss is a fast-growing entrepreneurial company, whose products are used in leading clinics across Europe and are backed by many years of clinical experience. The company prides itself in innovations, such as its maxgraft速 bonering for simultaneous implant placement and bone augmentation, as well as the maxgraft速 bonebuilder, a bone block customized for individual patients. Straumanns CEO, Marco Gadola commented: botiss will enable us to offer an unparalleled range of regenerative solutions to support implant and periodontal procedures. Their quality, effectiveness, handling characteristics and clinical track record will have great appeal to our customers as will the possibility to obtain every component for a complete solution from one company. botiss specializes in biomaterials for dental bone and tissue regeneration. Having gained a leading position in Europe, the company is looking to establish itself in other regions. botiss is privately owned and was founded by its two managing partners, Oliver Bielenstein and Dr Dra転en Tadi, in 2008. Dr Tadi noted: Our products, fields of interest and geographical footprints complement each other perfectly. Straumanns leadership in implant dentistry, its global strength and sales channels will help drive our geographic expansion. The possibilities of brand leverage and of distributing Emdogain are highly attractive and will benefit our partners in Eastern Europe and the Middle East. The two companies plan to begin distributing the respective products in initial countries in October 2014 and will work together to expedite regulatory clearances in American and Asian markets.
  • 2. Page 2/3 ITI World Symposium provides excellent platform for new research and products With more than 4000 participants, the ITI World Symposium is the leading academic event in oral implantology. Straumann is benefitting from this years event in Geneva to announce the roll-out of several innovative products and solutions, in addition to promoting its products through research updates. Roxolid速 minimally invasive implants1 now available throughout Europe Following initial introductions in selected markets, Straumanns full range of Roxolid implants is now available throughout Europe. This includes the small-diameter and 4mm short implant versions, which reduce invasiveness by avoiding bone augmentation procedures. Presentations in Geneva will refer to two and five year data for the 4mm implant2,3 and three- year clinical data on reduced-diameter implants4 , showing high survival rates and minimal marginal bone loss. Clinicians observations that short implants can lead to fewer complications, less morbidity, lower costs and more predictable outcomes5 will also be discussed. These and other factors make short implants an attractive option, often providing a completely different strategy for implant placement. Straumann速 PURE Ceramic Implant officially launched Straumanns innovative ceramic implant, which was presented at the EAO last October, has completed its controlled market release. Based on the positive feedback and clinical results (97.6% success and survival rates6 ), which will be presented in Geneva, the implant is now generally available to customers in Europe under the brand name Straumann速 PURE. The implant has exceptional esthetic properties with a translucent ivory color like natural tooth roots. It has a specially-developed ZLA速 surface to enhance and shorten the healing process and to provide highly predictable osseointegration. Its manufacture involves several innovations including a test procedureto assure the stability of every implant. New prosthetic components for fixed full-arch restorations To address the challenging needs of edentulous patients who want reliable, esthetic, full-arch dentures that are fixed, rather than removable, Straumann is introducing a new range of screw-retained implant abutments that offer increased flexibility. In addition to having low profiles, the new abutments are available with 17属 and 30属 angulations for challenging situations where the posterior implant has to be tilted. Straumann is also preparing the launch of new custom-milled framework components for final fixed prostheses. Broader CADCAM options with efficiency and productivity gains The Group is also announcing further enhancements to its CADCAM system. The latest software release, CARES速 Visual 8.8, offers further streamlined prosthetic solutions and a broader range of product combinations. The CARES X-Stream workflow, which significantly reduces turnaround time and shipping costs, can now be used for Straumanns Variobase abutment. Numerous restorative options are available for the latter, which offers a highly cost-effective, complete prosthetic solution with an original Straumann connection. For customers who want CADCAM custom prosthetics but do not have the requisite scanning capabilities, Straumann offers a Scan&Shape service, which has also been enhanced with additional functionality. 3M ESPE Trusted Connection Straumann and 3M ESPE are jointly announcing a trusted connection for the 3M True Definition Scanner. This enables dentists7 to obtain original CARES prosthetic solutions for implant- or tooth-borne restorations from just a single intra-oral scan and through a seamless workflow. The trusted connection is a further example of how Straumann is teaming up with leading providers to offer more options, simpler solutions, greater precision and higher productivity to dental professionals. Together with 3M ESPE, Dental Wings and Innovation
  • 3. Page 3/3 MediTech, Straumann offers a completely digital workflow from digital impression to finished CAM prosthetic with an excellent level of choice, flexibility and precision Further details of the aforementioned Straumann solutions are published in the current edition of Starget (www.straumann.com/starget). About Straumann Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners. Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland. Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01 E-mail: corporate.communication@straumann.com / investor.relations@straumann.com Homepage: www.straumann.com Contacts: Corporate Communication: Mark Hill, +41 (0)61 965 13 21 Thomas Konrad, +41 (0)61 965 15 46 Investor Relations: Fabian Hildbrand, +41 (0)61 965 13 27 Disclaimer This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. # # # 1 Less loss of biological tissues because of smaller implant bed and in case of reduced number of soft and hard tissue augmentation. 2 Slotte C, Gr淡nningsaeter A, Halm淡y AM, hrnell LO, Stroh G, Isaksson S, Johansson L, Mordenfeld A, Eklund J, Embring J. Four-millimeter implants supporting fixed partial dental prostheses in the severely resorbed posterior mandible: two-year results. Clin Implant Dent Relat Res. 2012 May;14 Suppl 1:e46-58. Epub 2011 May 20. 3 Slotte C, Gronningsaeter A, Halmoy, AM, Ohrnell LA, Mordenfeld A, Isaksson S, Johansson LA: Four-millimeter-long posterior- mandible implants: 5-year outcomes of a prospective multicenter study. Clin Implant Dent Realt Res. (submitted) 4 Quirynen M, Al-Nawas B, Meijer HJ, Razavi A, Reichert TE, Schimmel M, Storelli S, Romeo E; the Roxolid Study Group. Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double- blind, randomized controlled trial. Clin Oral Implants Res. 2014 Apr 9. [Epub ahead of print] 5 H辰mmerle C: Interview published in Starget 1/2014. Cochran D: Presentation at the Straumann Corporate Forum, EAO Dublin 2013. Al-Nawas B, H辰mmerle C: Presentations at the Straumann Corporate Forum, ITI World Symposium, Geneva 2014. 6 Gahlert M, Kniha H, Weingart D, Schild S, Eicholz P, Nickles K, Borman K-H, Prospective Open Label Single Arm Study to Evaluate the Performance of Straumann Ceramic Implants Monotype CIM (Zirconium dioxide) in single tooth gaps in the maxilla and mandible. EAO 2013, Poster 252, Clin. Oral Impl. Res. 24 (Suppl. s9), 2013, p. 123. 7 Available initially in US, Iberia and Benelux.